First-Line Pembrolizumab-Combination Therapy for Advanced Squamous NSCLC: Real-World Outcomes at US Oncology Practices

In KEYNOTE-407, median overall survival (OS) was 17.1 months (95% CI, 14.4-19.9); 12- and 24-month OS rates were 64.7% and 37.5%, respectively; and median duration of exposure was 7.1 months (range, 0.03-26.3) for patients with metastatic squamous NSCLC treated with first-line pembrolizumab plus carboplatin and paclitaxel/nab-paclitaxel (pembrolizumab-chemotherapy). This study aimed to examine real-world time on treatment (rwToT) and OS among patients with advanced squamous NSCLC treated with first-line pembrolizumab-chemotherapy at US oncology practices.